Investor Relations

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Mar 21, 2023
Clinical update of allo-iNKTs (agenT-797) in solid tumors to be presented at AACR Annual Meeting in April 2023 AgenT-797 in combination with pembro or nivo in NSCLC and gastric cancer to initiate in 2023 Allogeneic CAR platform demonstrates differentiation with IL-15-FAP-CAR-iNKT (MiNK-215) and
Corporate Presentation

SEC Filings

Form Description Filing date View
10-K

Annual report which provides a comprehensive overview of the company for the past year

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML

Data provided by Kaleidoscope.

Events and Presentations